Home Ingredients EatLess® (Yeast-Hydrolysate Satiety Peptide — Anderson)
Weight Management

EatLess® (Yeast-Hydrolysate Satiety Peptide — Anderson)

Saccharomyces cerevisiae
Evidence Level
Limited
0 Clinical Trials
3 Documented Benefits
2/5 Evidence Score

EatLess® is a yeast (Saccharomyces cerevisiae) hydrolysate peptide complex from Anderson Global Group, developed to support appetite control and satiety for weight management. Two small published trials of yeast hydrolysate, both from the academic group that developed the ingredient, found reductions in body weight and abdominal fat in obese adults; no independent group has replicated this.

Studied Dose 1,000 mg/day (0.5 g twice daily) in the 10-week obesity trial; 500 mg/day in the smaller low-dose trial. Lower amounts sometimes suggested for this ingredient were not tested in these trials.
Active Compound Yeast (Saccharomyces cerevisiae) hydrolysate peptide complex.

Benefits

Appetite control

In two small trials, obese participants taking yeast hydrolysate recorded lower calorie intake than the control group, which is the likely route to any weight effect. Both trials came from the group that developed the ingredient.

Weight-management support

In a 10-week placebo-controlled trial of about 54 obese adults, 1 g/day cut body weight by roughly 2.6 kg and reduced abdominal fat more than placebo; a smaller trial in 30 women at 0.5 g/day showed similar reductions. Both trials were small and came from the ingredient's developers, with no independent confirmation.

Limited-evidence note

The human evidence is two small trials from the academic group that developed the ingredient, with no independent replication, so keep expectations modest.

Mechanism of action

1

Satiety-hormone signaling

In rats, yeast hydrolysate altered appetite-related signals in the hypothalamus (including neuropeptide Y). In the human trials the measured effect was lower energy intake; specific satiety hormones such as CCK or GLP-1 have not been shown to change with this ingredient in people.

2

Appetite regulation

In the human trials, participants taking yeast hydrolysate recorded lower food intake than the control group.

Clinical trials

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Mild digestive upset is occasionally reported.
As a yeast-derived product, it may not suit people with a known yeast allergy or sensitivity.

Important Drug interactions

No major drug interactions are established for this ingredient.
Tell your doctor about all supplements if you take prescription medication.
Use caution if pregnant, breastfeeding, or managing a health condition.

Featured in these supplement guides

Weight Loss→

More Weight Management Ingredients

Weight Management
Glucomannan (Konjac Root Fiber)
Glucomannan is a water-soluble dietary fiber derived from the root of the konjac plant (Am…
Weight Management
Capsaicin / Capsicum Extract (Cayenne Pepper)
Capsicum extract (cayenne pepper, red chili pepper) and its primary bioactive capsaicin ar…
Weight Management
Metabolaid® (Hibiscus + Lemon Verbena)
Metabolaid® (Monteloeder/SuanNutra) is a patented combination of Hibiscus sabdariffa and L…
Weight Management
Trpti™ (Bioavailable Oleoylethanolamide / OEA — Saanroo)
Trpti™ (Hindi for 'satisfaction') is Saanroo's branded bioavailable oleoylethanolamide (OE…

Related articles from our blog

📝 Article
Peptides: Which Are Legal Supplements, and Which Are Not
Peptides are having a moment. They are in face serums and protein powders, in viral videos about "peptide therapy" and w…

Frequently asked questions about EatLess® (Yeast-Hydrolysate Satiety Peptide — Anderson)

What is EatLess?

EatLess® is a yeast (Saccharomyces cerevisiae) hydrolysate peptide complex from Anderson Global Group, developed to support appetite control and satiety for weight management.

What is EatLess used for?

EatLess is researched primarily for Weight Management. In two small trials, obese participants taking yeast hydrolysate recorded lower calorie intake than the control group, which is the likely route to any weight effect. Both trials came from the group that developed the ingredient.

What is the recommended dosage of EatLess?

The clinically studied dose is 1,000 mg/day (0.5 g twice daily) in the 10-week obesity trial; 500 mg/day in the smaller low-dose trial. Lower amounts sometimes suggested for this ingredient were not tested in these trials. Always follow the product label and check with a healthcare provider for personal advice.

Is EatLess safe, and does it have side effects?

For most healthy adults, EatLess is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. Mild digestive upset is occasionally reported. It may also interact with some medications. EatLess is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does EatLess interact with any medications?

Possible interactions include: No major drug interactions are established for this ingredient. Tell your doctor about all supplements if you take prescription medication. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for EatLess?

NutraSmarts rates the evidence for EatLess as Limited (2 out of 5). It is backed by 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Jung EY, Cho MK, Hong YH, Kim JH, Park Y, Chang UJ, Suh HJ Yeast hydrolysate can reduce body weight and abdominal fat accumulation in obese adults Nutrition. 2014;Nutrition. 2014 Jan;30(1):25-32. doi:10.1016/j.nut.2013.02.009..PubMedUsed to support: In a 10-week randomized placebo-controlled trial of obese men and women (about 54 participants), 1 g/day of yeast hydrolysate reduced body weight (-2.60 kg vs +0.83 kg in placebo, P<0.001), BMI and total abdominal fat area (-17.34 vs -7.06 cm2, P<0.01), through lower energy intake, without loss of lean mass. The trial was small and was run by the academic group that developed the ingredient.
  2. Jung EY, Lee JW, Hong YH, Chang UJ, Suh HJ Low Dose Yeast Hydrolysate in Treatment of Obesity and Weight Loss Preventive Nutrition and Food Science. 2017;Prev Nutr Food Sci. 2017 Mar;22(1):45-49. doi:10.3746/pnf.2017.22.1.45..PubMedUsed to support: In a small 8-week trial, 30 obese women took 0.5 g/day of yeast hydrolysate or a control; the yeast group had significant reductions in body weight, BMI, body fat and calorie intake. The study was small, included only women, and came from the same developer-affiliated group, with no independent replication.